Arcus Biosciences is expected to report Q3 2026 revenue of $7.58 million and a consensus EPS loss of -$0.92, with the stock currently trading at approximately $18.19 against an average analyst price target of $40.00.
The primary focus for investors remains the clinical trajectory of casdatifan, the company’s lead HIF-2α inhibitor, which recently showed promising kidney cancer data.
The projected 70% year-over-year revenue decline highlights the lumpy, milestone-dependent nature of the company's collaboration-based business model. Furthermore, analysts will scrutinize the preliminary cash balance of $694 million to gauge the sustainability of late-stage pipeline development through upcoming pivotal readouts.